IRulya Therapeutics Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Dirk Thye
- Full Time Employees
- 38
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 611 Gateway Boulevard South San Francisco CA United States of America 94080
- IPO Date
- May 9, 2019
- CIK
- 0001662774
- Website
- quincetx.com
- Similar Companies
- Business
- IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.
Company News
IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference
Quince Therapeutics (NASDAQ: QNCX) renames itself IRulya and sets IRLA ticker
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
Quince Therapeutics Stockholders Approve PIPE, Share Increase and Equity Plans
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
Quince Therapeutics to Participate in September 2026 Investor Conferences
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript
UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
Quince Therapeutics Settles Approximately $16.4 Million of Debt
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of “Reduce” by Analysts
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of “Reduce” by Analysts
What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours